Former CPhA chief pharmacy officer Danielle Paes will head the organization's Canadian expansion, with a focus on strengthening the mental health of healthcare professionals.
Across Canada, some jurisdictions have already approved or are working towards expanding the scope of certified pharmacists to include the administration of Sublocade.
Adding to the challenge is the current lack of widespread screening programs for early stage T1DM in the general population, making it difficult to identify all patients who may benefit from teplizumab.